【摘要】：目的研究惡性血液病患者侵襲性肺曲霉菌感染(IPA)抗真菌治療效果及其影響因素,為臨床資料提供參考依據(jù)。方法選擇2008年1月-2013年4月收治的82例患者,根據(jù)不同的用藥方案隨機分為伏立康唑組28例、卡泊芬凈組27例、聯(lián)合組27例3組,比較各組患者的臨床療效、不良反應(yīng),并對療效的影響因素,采用SAS9.0軟件進行分析。結(jié)果共調(diào)查惡性血液病患者241例,其中IPA 82例,感染率為34.0%;聯(lián)合組的抗真菌療效顯著優(yōu)于伏立康唑組、卡泊芬凈組(P0.05);單藥與兩藥聯(lián)合用藥的不良反應(yīng)差異無統(tǒng)計學(xué)意義;年齡≥50歲、接受造血干細胞移植(HSCT)、人類白細胞抗原(HLA)不匹配及既往IPA病史等均是IPA抗真菌治療療效的影響因素(P0.05)。結(jié)論伏立康唑與卡泊芬凈聯(lián)合用藥的療效優(yōu)于單藥,且不增加不良反應(yīng);年齡、HSCT、HLA不匹配及既往IPA病史等可影響療效。
[Abstract]:Objective to study the effect of anti-fungal treatment of invasive pulmonary aspergillosis (IPA) in patients with malignant hematological disease and its influencing factors, so as to provide reference for clinical data. Methods from January 2008 to April 2013, 82 patients were randomly divided into three groups according to different drug regimen, 28 patients in valiconazole group, 27 patients in kapofenjing group and 27 patients in combination group. The clinical effects and adverse reactions of each group were compared. The influencing factors of curative effect were analyzed by SAS9.0 software. Results A total of 241cases of malignant hematological diseases were investigated, among which 82 cases were IPA, the infection rate was 34.0%, the antifungal effect of the combined group was significantly better than that of the Voliconazole group and the kapofenjing group (P0.05). There was no significant difference in adverse reactions between single and combined drugs. Age 鈮，

本文編號：2441202